Publications / Dissemination

Peer Reviewed Publications

  • Organotypic retinal explant cultures as in vitro alternative for diabetic retinopathy studies.
    Valdés J, Trachsel-Moncho L, Sahaboglu A, Trifunović D, Miranda M, Ueffing M, Paquet-Durand F, Schmachtenberg O.
    ALTEX. 2016 May 9. doi: 10.14573/altex.1603111.
    Pubmed
  • Sothilingam V, Garcia Garrido M, Jiao K, Buena-Atienza E, Sahaboglu A, Trifunović D, Balendran S, Koepfli T, Mühlfriedel R, Schön C, Biel M, Heckmann A, Beck SC, Michalakis S, Wissinger B, Seeliger MW, Paquet-Durand F. Retinitis pigmentosa: impact of different Pde6a point mutations on the disease phenotype. Hum Mol Genet. 2015 Oct 1; 24(19): 5486-99. doi: 10.1093/hmg/ddv275. Epub 2015 Jul 17.
    Pubmed
  • Kulkarni M, Schubert T, Baden T, Wissinger B, Euler T, F. Imaging Ca2+ dynamics in cone photoreceptor axon terminals of the mouse retina. J Vis Exp. 2015 May 6; (99): e52588. doi: 10.3791/52588.
    Pubmed
  • Ekström PA, Ueffing M, Zrenner E, Paquet-Durand F. Novel in situ activity assays for the quantitative molecular analysis of neurodegenerative processes in the retina. Curr Med Chem. 2014; 21(30): 3478-93
    Pubmed
    Paquet-Durand F, Sahaboglu A, Dietter J, Paquet-Durand O, Hitzmann B, Ueffing M, Ekström PA. How long does a photoreceptor cell take to die? Implications for the causative cell death mechanisms. Adv Exp Med Biol. 2014; 801: 575-81. doi: 10.1007/978-1-4614-3209-8_73.
    Pubmed
  • Arango-Gonzalez B, Leitritz M, Fischer D, Gerberding M, Paquet-Durand F, Ueffing M. Therapieansätze für erbliche Netzhauterkrankungen: von den Genen bis zum Chip. Klinische Monatsblätter für Augenheilkunde 2014; Vol. 231/Issue 03: 222-231.
  • Du J, Cleghorn WM, Contreras L, Lindsay K, Rountree AM, Chertov AO, Turner SJ, Sahaboglu A, Linton J, Sadilek M, Satrústegui J, Sweet IR, Paquet-Durand F, Hurley JB. Inhibition of mitochondrial pyruvate transport by zaprinast causes massive accumulation of aspartate at the expense of glutamate in the retina. J Biol Chem. 2013 Dec 13; 288(50): 36129-40. doi: 10.1074/jbc.M113.507285. Epub 2013 Nov 1.
    Pubmed
  • Sahaboglu A, Paquet-Durand O, Dietter J, Dengler K, Bernhard-Kurz S, Ekström PA, Hitzmann B, Ueffing M, Paquet-Durand F. Retinitis pigmentosa: rapid neurodegeneration is governed by slow cell death mechanisms. Cell Death Dis. 2013 Feb 7; 4: e488. doi: 10.1038/cddis.2013.12.
    Pubmed

Dissemination Activities

Oral presentations:

  • Partner 1, EKUT; The DRUGSFORD project: An update on the pre-clinical development. ARVO annual meeting, Retina International Scientific and Medical Advisory Board Meeting, Seattle, USA, May 2016.
  • Partner 5, ULUND; presentation title: cGMP in retinal degeneration. New ideas for an old problem; Nordic Retina Meeting, Bergen, Norway, May 2015.
  • Partner 1, EKUT; presentation title: The DRUGSFORD project: Orphan drug status obtained for the first lead compound formulation; ARVO annual meeting, Retina International Scientific and Medical Advisory Board Meeting, Denver, USA, May 2015.
  • Partner 3, BIOLOG; presentation title: Development of Prodrugs of cNMPS analogs - from early pitfalls to final success?; 12th Biochemistry Retreat AG Herberg, Wesendorf, Germany, January 2015.
  • Partner 3, BIOLOG; presentation title: Development of prodrugs of cNMP(S) analogs - from early pitfalls to final success? FOR 2060 Meeting on “New Developments in Signal Transduction & cGMP Research“, Rottenburg, Germany, January 2015.
  • Partner 1, EKUT; presentation title: Ein besseres Verständnis von neurodegenerativen Mechanismen als Grundlage für die Entwicklung neuartiger Therapien für erbliche Netzhautdegeneration; Patient Day of the ProRetina Germany e.V., Augsburg, Germany, October 2014
  • Partner 1, EKUT; presentation title: Developing New Drugs and Delivery Systems for the Treatment of Inherited Retinal Degeneration: The DRUGSFORD Project; ISOPT Clinical 2014- The 11th International Symposium on Ocular Pharmacology and Therapeutics, Reykjavik, Iceland, June 2014.
  • Partner 5, ULUND; presentation title: Inherited retinal degeneration; Mechanisms and experimental therapy; Professional meeting at the Eye Department, Haukeland’s University Hospital, concerning genetic retinal diseases, Bergen, Norway, March 2014.
  • Partner 5, ULUND; presentation title: Inherited photoreceptor degeneration: Mechanisms and experimental therapy; Gothenburg, Sweden, September 2013.

Poster presentations:

  • Partner 1, EKUT; poster title The DRUGSFORD project: Preservation of retinal morphology and function in different in vivo models for hereditary retinal degeneration.  Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), Seattle, USA, May 2016.
  • Partner 5, ULUND; poster title: Neuroprotection of degenerating rod photoreceptors by pharmacological interference with cyclic nucleotide-gated (CNG) channels and the cGMP-protein kinase; Neuroscience, 2014; Annual Meeting of Society of Neuroscience (SfN), Washington DC, USA, November 2014.
  • Partner 4, UNIMORE; poster title: Protective effects by inhibition of CNG channels and PKG activity in rd1 mutant photoreceptors;  Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), Orlando, USA, May 2014.

Article published in the popular press:

  • Partner 1, EKUT; Le projet "DRUGSFORD": Une initiative pour développer des nouveaux médicaments contre les dégénérescences héréditaires de la rétine. France, Circulaire IRRP (Information Recherche Rétinite Pigmentaire); February 2016.
  • Partner 1, EKUT; Les mécanismes de la mort cellulaire: Importance de leur compréhension pour le développement de nouveaux traitements des dégénérescences héréditaires de la rétine; France, Circulaire IRRP (Information Recherche Rétinite Pigmentaire); February 2014.